Zur Hauptnavigation wechseln Zur Suche wechseln Zum Hauptinhalt wechseln

Macrovascular tumor infiltration and circulating tumor cell cluster dynamics in patients with cancer approaching the end of life

Kelley Newcomer, Alessandro Bifolco, Sarah Reeves, Giada Pontecorvi, Simran Asawa, Magdalena K. Sznurkowska, Manuel Nüesch, Lauren L. Ozimski, Louisa Bolm, Malte Maria Sieren, Lukas Müller, Zhikai Chi, William Gasper, Megan B. Wachsmann, William Moore, Xue Zheng, Angelique Fokkema, Alexander Ring, Bich Doan Nguyen-Sträuli, Selina BudinjasMeike ten Winkel, Benedikt Färber, Abbas Zaki, Nafeesah Fatimah, Elena Crecca, John D. Karalis, Raghav Chandra, Hillary Prince, Kristina L. Goff, Sung Hee Choi, Carol Abousaab, Song Zhang, Suzanne Cole, Kathryn Naumann, Tobias Keck, Patricio M. Polanco, Ana Gvozdenovic, Ilona Krol, Francesc Castro-Giner, Carlos Arteaga, Herbert J. Zeh, Roman Kloeckner, Dario Ghersi, Nicola Aceto*, Matteo Ligorio*

*Korrespondierende/r Autor/-in für diese Arbeit

Abstract

End-of-life events related to carcinoma lethality are poorly characterized. Herein we conducted an observational, prospective, case–control study enrolling 21 patients with solid tumors and 10 patients without known malignancy, complemented by a retrospective validation cohort of 1,250 patients with cancer. In our prospective cohort, we observed spikes in circulating tumor cell (CTC) counts, particularly clusters, immediately before death (P < 0.0001), as well as pathological evidence of macrovascular infiltration and large-vessel occlusion obtained through rapid autopsy. In the validation cohort, radiological evidence of macrovascular infiltration emerged as the strongest predictor of poor survival—independent of metastasis—in treatment-homogeneous patients with colorectal, lung, ovarian, hepatocellular or pancreatic cancer (hazard ratios = 4.0–22.4). Collectively, these findings suggest that macrovascular infiltration and spikes in CTC clusters with consequent vascular failure could be pivotal end-of-life events associated with cancer lethality, providing a rationale for future trials aimed at curbing infiltration into large vessels.

OriginalspracheEnglisch
ZeitschriftNature Medicine
Jahrgang31
Ausgabenummer12
Seiten (von - bis)4140-4149
Seitenumfang10
ISSN1078-8956
DOIs
PublikationsstatusVeröffentlicht - 12.2025

Fördermittel

Research in the Ligorio laboratory is supported by the Cancer Prevention & Research of Texas Recruitment of First-Time Tenure-Track Faculty Members Grant (RR200023), an R37 National Institute of Health Cancer Institute Grant (5R37CA242070), American-Italian Cancer Foundation Post-Doctoral Research Fellowship to Giada Pontecorvi, PhD (2022–2024), and the Department of Surgery and the Harold C. Simmons Comprehensive Cancer Center at UTSW Medical Center. A special thanks to the current and previous members of the Ligorio laboratory, as well as R. Hammer, S. Comerford, R. Napier, C. Lewis, R. Nix, T. Harris and C. Rodriguez, for their support. Research in the Aceto laboratory is supported by the European Research Council (101001652), the strategic focus area of Personalized Health and Related Technologies at ETH Zurich (PHRT-960), the Swiss National Science Foundation (212183), the Swiss Cancer League (KLS-5636-08-2022), the ETH Lymphoma Challenge (LC-02-22) and ETH Zürich. We acknowledge the assistance of the University of Texas Southwestern Tissue Management Shared Resource, a shared resource at the Simmons Comprehensive Cancer Center, which is supported in part by the National Cancer Institute (award P30 CA142543). We would also like to thank the UTSW Willed Body Program, as well as Visiting Nurse Association Hospice of Texas, Faith Presbyterian Hospice and Pathway Hospice for their partnership on this project and for hospice patients and their families.

TrägerTrägernummer
Faith Presbyterian Hospice and Pathway Hospice
Visiting Nurse Association Hospice of Texas
Department of Surgery
American-Italian Cancer Foundation
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung212183
Eidgenössische Technische Hochschule ZürichPHRT-960
National Cancer Institute5R37CA242070, P30 CA142543
European Research Council101001652
Krebsliga SchweizKLS-5636-08-2022, LC-02-22

    UN SDGs

    Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

    1. SDG 3 – Gesundheit und Wohlergehen
      SDG 3 – Gesundheit und Wohlergehen

    Strategische Forschungsbereiche und Zentren

    • Profilbereich: Lübeck Integrated Oncology Network (LION)
    • Forschungsschwerpunkt: Biomedizintechnik

    DFG-Fachsystematik

    • 2.22-14 Hämatologie, Onkologie
    • 2.22-25 Allgemein- und Viszeralchirurgie
    • 2.22-30 Radiologie

    Fingerprint

    Untersuchen Sie die Forschungsthemen von „Macrovascular tumor infiltration and circulating tumor cell cluster dynamics in patients with cancer approaching the end of life“. Zusammen bilden sie einen einzigartigen Fingerprint.

    Zitieren